Klöckner Pentaplast expanding Swiss facility to support EMEA growth

Comments Email

Klöckner Pentaplast’s pharmaceutical & medical device films division (kp Pharma) is investing €5m in its Bern, Switzerland facility, to increase production capacity by 30%, the German packaging firm announced 1 Feb.

The new capacity is expected to be operational by the end of 2018.

The company said the expansion aimed to address the “ever-changing market needs in EMEA and support expansion into Asia.”

According to Tracey Peacock, president, pharmaceutical & medical device films at kp, the company is currently seeing “substantial growth” in its barrier product segments in EMEA.

This is a result of the increased moisture and oxygen sensitivity of new drugs.

The new capacity will also support the Asian market as it continues to experience “double-digit” growth. 

According to Peacock, the company has been “quietly adding” to its capabilities in EMEA.

“Now we must accelerate addressing the growing Asian market place,” she added.

As regulations within the Asian market increase, and many EMEA and US standards are adopted in the region, kp can see strong growth opportunities.

“We are invigorated by the opportunities, and this expansion, supported by local manufacturing and slitting capability in Thailand and China, is just the beginning of some exciting plans we have.”

This latest investment follows another expansion in the company’s manufacturing centre in Montabaur, Germany, where additionally laminating capacity was installed two years ago.

Founded in 1965, Klöckner Pentaplast has operations in 18 countries and employs over 6,300 people in 61 locations, including 32 production sites.



Select from the list below to subscribe to customized Plastics News Europe e-mail news alerts. Check the options you wish to receive.